Clinical trial NCT04293042: Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients
Official title: A Pilot Study in the Treatment of BK Virus Infection With Cytotoxic T Cells in Immunocompromised Transplant Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: BK Polyomavirus
Lead sponsor: Children's Hospital of Philadelphia
Sponsor class: OTHER
First posted: 2020-03-03
Enrollment: 20
Sex: ALL
Minimum age (years): 5
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This open-label, single-arm clinical trial
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantation (HSCT), renal transplantation, and chemotherapy.

Detailed description: This open-label, single-arm clinical trial will assess the safety and efficacy of BK virus-specific CTLs isolated from whole blood or leukapheresis products. The BK virus -specific CTLs will be generated automatically by the CliniMACS® Prodigy using the CliniMACS Cytokine Capture System (IFNgamma) after incubation with MACS GMP PepTivator® Peptide Pools of BKV VP1 and BKV LT.

Eligibility criteria: Inclusion Criteria:

Patient Eligibility

* Patients with symptoms of cystitis and elevated BK virus DNA by screening PCR as above (section 4) post allogeneic HSCT, post chemotherapy

  1. Symptoms of cystitis may include: hematuria (microscopic or gross), pain with urination, frequency, bladder spasms.
  2. Patient may be otherwise treated for cystitis as per local institutional standards. Such treatments may include hydration, antiviral medications, or surgical intervention as deemed appropriate by treating physician.
* Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.
* Performance Status \> 30% (Lansky \< 16 yrs and Karnofsky \> 16 yrs)
* Age: 0.1 to 25 years
* Females of childbearing potential with a negative urine pregnancy test.

Donor Eligibility

* Related donor available with a T-cell response to the BK-virus MACS® PepTivator® antigen(s).

  1. Original allogeneic donor if available, IgG positive for BKV or confirmatory testing to respond to BKV MACS Peptivator®.
  2. Third Party Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party allogeneic donor (family donor \> 1 HLA A, B, DR match to recipient) with a T-cell response to the BK MACS® PepTivator.

     AND
* Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1).

AND

• Obtained informed consents by donor or donor legally authorized representative prior to donor collection.

Exclusion Criteria:

Patient exclusion criteria:

A patient meeting any of the following criteria is not eligible for the present study:

* Patient with acute GVHD \> grade 2 or extensive chronic GVHD at the time of BK Virus CTL infusion
* Patient receiving steroids (\>0.5 mg/kg prednisone equivalent) at the time of BK Virus CTL infusion or within 3 days of planned infusion.
* Thymoglobulin (ATG), campath or T cell immunosuppressive monoclonal antibodies within 30 days
* Patient with poor performance status determined by Karnofsky (patients \>16 years) or Lansky (patients ≤16 years) score ≤30%
* Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory BK virus infection.
* Any medical condition which could compromise participation in the study according to the investigator's assessment
* Known HIV infection
* Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment.
* Known hypersensitivity to iron dextran
* Patients unwilling or unable to comply with the protocol or unable to give informed consent.
* Known human anti-mouse antibodies

Primary outcomes:
measure: Number of participants with Grade III-IV acute GVHD
timeFrame: Up to 8 weeks after last BK-CTL infusion
measure: Number of patients with undetectable BK viral load
timeFrame: 12 weeks after first BK-CTL infusion
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Children's Hospital of Philadelphia
state: Pennsylvania
Study officials:
affiliation: Children's Hospital of Philadelphia
name: Caitlin Elgarten, MD, MSCE
role: PRINCIPAL_INVESTIGATOR
References: